• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Day One Biopharmaceuticals Inc. (Amendment)

    10/20/23 4:01:56 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DAWN alert in real time by email
    SC 13D/A 1 d514379dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

     

    Day One Biopharmaceuticals, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    23954D109

    (CUSIP Number)

    Alejandro Moreno

    Langhorne S. Perrow

    c/o Access Industries, Inc.

    40 West 57th Street, 28th Floor

    New York, New York 10019

    (212) 247-6400

    with copies to:

    Nicholas P. Pellicani

    Debevoise & Plimpton LLP

    65 Gresham Street

    EC2V 7NQ

    London

    +44 20 7786 9000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    October 18, 2023

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rules 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐

     

     

     


    CUSIP No. 23954D109

     

     1   

     NAME OF REPORTING PERSON.

     

     AI Day1 LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

     AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     State of Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     12,929,322 shares

        8  

     SHARED VOTING POWER

     

     0 shares

        9  

     SOLE DISPOSITIVE POWER

     

     12,929,322 shares

       10  

     SHARED DISPOSITIVE POWER

     

     0 shares

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     12,929,322 shares

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);

     

     14.87%(1)

    14  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO (Limited Liability Company)

     

    (1)

    All percentages of ownership of Common Stock by the Reporting Persons presented in this Statement are based on an aggregate of 86,973,819 shares of Common Stock issued and outstanding as of August 1, 2023, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 7, 2023.


    CUSIP No. 23954D109

     

     1   

     NAME OF REPORTING PERSON.

     

     Access Industries Holdings LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

     AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     State of Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0 shares

        8  

     SHARED VOTING POWER

     

     12,929,322 shares

        9  

     SOLE DISPOSITIVE POWER

     

     0 shares

       10  

     SHARED DISPOSITIVE POWER

     

     12,929,322 shares

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     12,929,322 shares

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);

     

     14.87%(1)

    14  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO (Limited Liability Company)

     

    (1)

    All percentages of ownership of Common Stock by the Reporting Persons presented in this Statement are based on an aggregate of 86,973,819 shares of Common Stock issued and outstanding as of August 1, 2023, as reported in the Issuer’s Form 10-Q filed with the SEC on August 7, 2023.


    CUSIP No. 23954D109

     

     1   

     NAME OF REPORTING PERSON.

     

     Access Industries Management, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

     AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     State of Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0 shares

        8  

     SHARED VOTING POWER

     

     12,929,322 shares

        9  

     SOLE DISPOSITIVE POWER

     

     0 shares

       10  

     SHARED DISPOSITIVE POWER

     

     12,929,322 shares

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     12,929,322 shares

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);

     

     14.87%(1)

    14  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO (Limited Liability Company)

     

    (1)

    All percentages of ownership of Common Stock by the Reporting Persons presented in this Statement are based on an aggregate of 86,973,819 shares of Common Stock issued and outstanding as of August 1, 2023, as reported in the Issuer’s Form 10-Q filed with the SEC on August 7, 2023.


    CUSIP No. 23954D109

     

     1   

     NAME OF REPORTING PERSON.

     

     Len Blavatnik

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

     AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0 shares

        8  

     SHARED VOTING POWER

     

     12,929,322 shares

        9  

     SOLE DISPOSITIVE POWER

     

     0 shares

       10  

     SHARED DISPOSITIVE POWER

     

     12,929,322 shares

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     12,929,322 shares

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);

     

     14.87%(1)

    14  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN

     

    (1)

    All percentages of ownership of Common Stock by the Reporting Persons presented in this Statement are based on an aggregate of 86,973,819 shares of Common Stock issued and outstanding as of August 1, 2023, as reported in the Issuer’s Form 10-Q filed with the SEC on August 7, 2023.


    CONTINUATION PAGES TO AMENDMENT NO. 3 TO SCHEDULE 13D

    This Amendment No. 3 to Schedule 13D is being filed by AI Day1 LLC (“AI Day1”), Access Industries Holdings LLC (“AIH”), Access Industries Management, LLC (“AIM”) and Len Blavatnik (collectively, the “Reporting Persons”, and each, a “Reporting Person”), in respect of the common stock, par value $0.0001 per share (the “Common Stock”), of Day One Biopharmaceuticals, Inc. (the “Issuer”).

    The Schedule 13D filed with the Securities and Exchange Commission (“SEC”) on June 9, 2021, as amended by supplemented by Amendment No. 1 to the Schedule 13D filed by the Reporting Persons with the SEC on June 21, 2022 and Amendment No. 2 to the Schedule 13D filed by the Reporting Persons with the SEC on June 12, 2023 (together, the “Schedule”) is hereby amended and supplemented by the Reporting Persons as set forth below in this Amendment No. 3. This amendment is filed by the Reporting Persons in accordance with Rule 13d-2 of the Securities Exchange Act of 1934, as amended, and refers only to information that has materially changed since the filing of the Schedule. The items identified below, or the particular paragraphs of such items which are identified below, are amended as set forth below. Unless otherwise indicated, all capitalized terms used and not defined herein have the respective meanings assigned to them in the Schedule.

    Item 3 Source and Amount of Funds or Other Considerations

    The disclosure in Item 3 is hereby supplemented by adding the following at the end thereof:

    On October 18, 2023, AI Day 1 purchased 979,667 shares of Common Stock at a weighted average price of $10.2076 per share in open market transactions.1 AI Day 1 funded these purchases using capital contributed from affiliated entities, which funded that capital using cash on hand.

    On October 19, 2023, AI Day 1 purchased 384,400 shares of Common Stock at a weighted average price of $10.0608 per share in open market transactions.2 AI Day 1 funded these purchases using capital contributed from affiliated entities, which funded that capital using cash on hand.

    On October 20, 2023, AI Day 1 purchased 111,387 shares of Common Stock at a weighted average price of $9.9734 per share in open market transactions.3 AI Day 1 funded these purchases using capital contributed from affiliated entities, which funded that capital using cash on hand.

    Item 5 Interest in Securities of the Issuer

    The disclosure in Item 5(a), (b) (and (c) is hereby amended and restated as follows:

    (a) and (b) The responses of each of the Reporting Persons with respect to Rows 11, 12, and 13 of the cover pages of this Schedule 13D that relate to the aggregate number and percentage of common stock (including but not limited to footnotes to such information) are incorporated herein by reference.

    The responses of each of the Reporting Persons with respect to Rows 7, 8, 9, and 10 of the cover pages of this Schedule 13D that relate to the number of common stock as to which each of the persons or entities referenced in Item 2 above has sole or shared power to vote or to direct the vote of and sole or shared power to dispose of or to direct the disposition of (including but not limited to footnotes to such information) are incorporated herein by reference.

     

    1 

    The shares were purchased in multiple transactions ranging from $10.07 to $10.29, inclusive. The Reporting Persons undertake to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.

    2 

    The shares were purchased in multiple transactions ranging from $9.88 to $10.20, inclusive. The Reporting Persons undertake to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.

    3 

    The shares were purchased in multiple transactions ranging from $9.83 to $10.13, inclusive. The Reporting Persons undertake to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.


    12,929,322 shares of Common Stock are owned directly by AI Day1 and may be deemed to be beneficially owned by AIH, AIM and Mr. Blavatnik because (i) AIH indirectly controls all of the outstanding voting interests in AI Day1, (ii) AIM controls AIH and (iii) Mr. Blavatnik controls AIM and controls a majority of the outstanding voting interests in AIH. Each of the Reporting Persons (other than AI Day1), and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities.

    (c) The following transactions in the Issuer’s securities have been effected by Reporting Persons within the 60 days prior to this filing:

    The information set forth in Item 3 of this Schedule 13D is incorporated by reference herein.

    Item 7 Materials to Be Filed as Exhibits

    The disclosure in Item 7 is hereby supplemented by adding the following at the end thereof:

     

    Exhibit    Description
    99.9    Joint Filing Agreement, dated as of October 20, 2023.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: October 20, 2023

     

    AI DAY1 LLC       By: Access Industries Management, LLC, its Manager
         

    /s/ Alejandro Moreno

          Name: Alejandro Moreno
          Title: Executive Vice President

     

    ACCESS INDUSTRIES HOLDINGS LLC       By: Access Industries Management, LLC, its Manager
         

    /s/ Alejandro Moreno

          Name: Alejandro Moreno
          Title: Executive Vice President

     

    ACCESS INDUSTRIES MANAGEMENT, LLC      

    /s/ Alejandro Moreno

          Name: Alejandro Moreno
          Title: Executive Vice President
         

    *

          Name: Leonard Blavatnik

     

    *

    The undersigned, by signing his name hereto, executes this Amendment No. 3 to Schedule 13D pursuant to the Limited Power of Attorney executed on behalf of Mr. Blavatnik and filed herewith.

     

        By:  

    /s/ Alejandro Moreno

          Name: Alejandro Moreno
          Attorney-in-Fact
    Get the next $DAWN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DAWN

    DatePrice TargetRatingAnalyst
    10/9/2024$32.00 → $33.00Buy
    Needham
    8/1/2024$11.00 → $24.00Underperform → Buy
    BofA Securities
    4/24/2024$30.00 → $33.00Buy
    Needham
    4/25/2023$34.00 → $9.00Buy → Underperform
    BofA Securities
    2/8/2023$40.00Overweight
    CapitalOne
    2/3/2023Perform
    Oppenheimer
    12/15/2022$35.00Buy
    H.C. Wainwright
    12/14/2022$40.00Buy
    Needham
    More analyst ratings

    $DAWN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Day One Reports First Quarter 2025 Financial Results and Corporate Progress

      OJEMDA™ (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA™ (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, May 6, 4:30 p.m. ET BRISBANE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its first quarter 2025 financial results and highlighted recent corporate achievemen

      5/6/25 4:01:00 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025

      BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the first quarter 2025. Live audio of the webcast will be accessible on the Day One Investors & Media page. An archived version of the webcast will be available for replay on the Events & Presentations section of the Day One Investors & Media page for 30 days

      4/22/25 8:30:00 AM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

       Achieved Q4 2024 and full year 2024 OJEMDA™ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectively Ended 2024 with $531.7 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, February 25, 4:30 p.m. ET BRISBANE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its fourth quarter and full year 2024 financial results and highli

      2/25/25 4:05:00 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DAWN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • April 30, 2024 - FDA Roundup: April 30, 2024

      For Immediate Release: April 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

      4/30/24 3:20:20 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • April 26, 2024 - FDA Roundup: April 26, 2024

      For Immediate Release: April 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

      4/26/24 3:10:22 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for OJEMDA issued to DAY ONE BIOPHARMACEUTICALS INC

      Submission status for DAY ONE BIOPHARMACEUTICALS INC's drug OJEMDA (ORIG-1) with active ingredient TOVORAFENIB has changed to 'Approval' on 04/23/2024. Application Category: NDA, Application Number: 218033, Application Classification: Type 1 - New Molecular Entity

      4/24/24 12:52:43 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DAWN
    Financials

    Live finance-specific insights

    See more
    • Day One Reports First Quarter 2025 Financial Results and Corporate Progress

      OJEMDA™ (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA™ (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, May 6, 4:30 p.m. ET BRISBANE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its first quarter 2025 financial results and highlighted recent corporate achievemen

      5/6/25 4:01:00 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025

      BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the first quarter 2025. Live audio of the webcast will be accessible on the Day One Investors & Media page. An archived version of the webcast will be available for replay on the Events & Presentations section of the Day One Investors & Media page for 30 days

      4/22/25 8:30:00 AM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

       Achieved Q4 2024 and full year 2024 OJEMDA™ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectively Ended 2024 with $531.7 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, February 25, 4:30 p.m. ET BRISBANE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its fourth quarter and full year 2024 financial results and highli

      2/25/25 4:05:00 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DAWN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Day One Biopharmaceuticals Inc.

      10-Q - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)

      5/6/25 4:05:34 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Day One Biopharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)

      5/6/25 4:01:26 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Day One Biopharmaceuticals Inc.

      DEFA14A - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)

      4/11/25 4:03:10 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DAWN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Needham reiterated coverage on Day One Biopharmaceuticals with a new price target

      Needham reiterated coverage of Day One Biopharmaceuticals with a rating of Buy and set a new price target of $33.00 from $32.00 previously

      10/9/24 7:46:01 AM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Day One Biopharmaceuticals upgraded by BofA Securities with a new price target

      BofA Securities upgraded Day One Biopharmaceuticals from Underperform to Buy and set a new price target of $24.00 from $11.00 previously

      8/1/24 6:23:36 AM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on Day One Biopharmaceuticals with a new price target

      Needham reiterated coverage of Day One Biopharmaceuticals with a rating of Buy and set a new price target of $33.00 from $30.00 previously

      4/24/24 7:16:05 AM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DAWN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ai Day1 Llc bought $14,978,327 worth of shares (1,475,454 units at $10.15) (SEC Form 4)

      4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

      10/20/23 4:02:31 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DAWN
    Leadership Updates

    Live Leadership Updates

    See more
    • Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development

      Dr. Blackman's departure planned for end of 2024 Company's search for a new Head of R&D is ongoing BRISBANE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Samuel Blackman, M.D., Ph.D, co-founder and Head of Research & Development (R&D) of the Company, will be retiring effective at the end of 2024. He will continue to serve as a strategic advisor and consultant while the Company seeks a new Head of R&D. "Sam's passion for pediatric oncology

      11/20/24 4:30:00 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Day One Announces Two New Appointments to Board of Directors

      BRISBANE, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the appointments of Habib Dable and Dr. William Grossman to its Board of Directors. "We are excited to welcome Habib and Bill to our Board during this pivotal phase of our growth," said Jeremy Bender, Ph.D., chief executive officer of Day One. "Their deep expertise and leadership in oncology will further strengthen our Board and will be a great asset as we prepare for the potential launch of ou

      1/17/24 8:00:00 AM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Day One Appoints Garry Nicholson as Chairman of the Board of Directors

      SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the appointment of Garry Nicholson as chairman of its board of directors. Mr. Nicholson brings more than 30 years of pharmaceutical and biotech oncology experience and previously served as president of Pfizer Oncology where he led its global oncology franchise. Day One co-founder Julie Grant, who served as board chair since 2021, will continue to serve as a member of the board of directors. "Garry is an accompl

      9/12/22 8:30:00 AM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DAWN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Merendino Lauren claimed ownership of 28,552 shares (SEC Form 3)

      3 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

      2/28/25 7:50:59 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • COO, CFO AND SECRETARY York Charles N Ii converted options into 16,875 shares and sold $52,278 worth of shares (4,370 units at $11.96), increasing direct ownership by 5% to 252,638 units (SEC Form 4)

      4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

      2/21/25 6:10:03 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GENERAL COUNSEL Dubow Adam converted options into 12,086 shares and sold $55,580 worth of shares (4,646 units at $11.96), increasing direct ownership by 23% to 39,602 units (SEC Form 4)

      4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

      2/21/25 6:08:31 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DAWN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Day One Biopharmaceuticals Inc.

      SC 13G/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

      11/14/24 4:30:11 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Day One Biopharmaceuticals Inc.

      SC 13G/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

      11/7/24 9:24:55 AM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Day One Biopharmaceuticals Inc.

      SC 13G - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

      11/7/24 9:12:22 AM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care